Corise Pimocard Plus 5mg (Pimobendan & Benazepril) Chewable Tablets for Dogs
Inclusive of all taxes
Product Details
| Product type | Oral Palatable Chewable Tablets (Schedule H Prescription Drug) |
| Volume / Quantity | Pack of 30 Tablets (3 strips of 10 tablets per box) |
| Target Species | Canines Only (Dogs diagnosed with advanced cardiovascular disease, valvular insufficiency, or cardiac enlargement) |
| Common Use Case | Long-term therapeutic management of clinical congestive heart failure (CHF) stemming from Myxomatous Mitral Valve Disease (MMVD) or Dilated Cardiomyopathy (DCM); reduction of peripheral and systemic blood vessel congestion; delaying heart failure progression in pre-clinical DCM or mitral valve disease; providing secondary end-organ protection for kidneys (CKD management); and managing blood pressure to alleviate fatigue, chronic coughing, and exercise intolerance. |
Corise Pimocard Plus 5mg is an advanced, prescription-only dual-action veterinary cardiovascular medication meticulously formulated to manage clinical congestive heart failure (CHF) and structural heart diseases in dogs. This high-potency formula delivers a synergistic, fixed-dose combination of Pimobendan (5mg) and Benazepril Hydrochloride (10mg), fortified with Co-enzyme Q10 (20mg) to decrease cardiac workload, enhance cellular energy production, and improve life expectancy in pets suffering from advanced heart conditions.
Pimobendan functions as a premier "inodilator" by acting as a calcium sensitizer to directly increase myocardial contractility (positive inotropy) while selectively inhibiting the phosphodiesterase III (PDE3) enzyme to dilate blood vessels without significantly raising heart tissue oxygen demand. Working alongside it, Benazepril Hydrochloride operates as a potent Angiotensin-Converting Enzyme (ACE) inhibitor that suppresses the renin-angiotensin-aldosterone system (RAAS), preventing the conversion of angiotensin I to angiotensin II to relax blood vessels and lower systemic blood pressure. Together, this dual mechanism aggressively counteracts conditions like Myxomatous Mitral Valve Disease (MMVD) and Dilated Cardiomyopathy (DCM), easing fluid buildup (pulmonary edema) and noticeably lessening severe clinical symptoms like coughing, breathlessness, and extreme lethargy.